The Honest Dose #14

This is the 14th issue of The Honest Dose, which means this project is ~3.5 months old. I did the math this week and it caught me off guard. 3.5 months is not long. But it's long enough to look back at where this started and notice how much has changed, and how little of that change came from anything I planned. Almost all of it came from who showed up.

When I started, I was writing scoring logs mostly for myself. It was a way to force discipline onto how I read the evidence behind these compounds, to make myself defend every number instead of just having an impression. What I did not expect was that other people would find that useful, argue with it, sharpen it, and then stick around. The corrections I've gotten, the vendors people have asked me to score, the offhand questions that turned into entire issues: that isn't an audience, it's a group of people building this thing alongside me. I don't take that lightly, and I want to say it plainly. Watching this community grow has been the best part of my year.

Which is why I've been thinking about how to actually give something back to the people who have been reading since the early issues. I'm not going to announce anything I can't deliver, and I'm not going to tease a date I don't have. But there's something I'd like to put together specifically for readers, something with real practical value rather than a discount code on a coffee mug. It isn't ready yet. When it's real, you'll be the first to know. For now, just take this as a note that it's in the works. Stay tuned.

The reason I care about doing that carefully is the same reason I care about doing any of this carefully: the ground under this entire space is moving faster than it ever has. A few years ago, peptides were a niche interest with a small and slightly secretive following. Then GLP-1 drugs walked straight into the center of mainstream culture, and now almost everyone has a direct or one-degree-removed relationship with this class of compound, whether it's a parent on semaglutide, a coworker who won't stop talking about it, or their own prescription. That mainstreaming changes everything downstream of it. It pulls research funding, regulatory attention, and ordinary public curiosity toward a category that used to live in the margins.

And it means the next compound that reshapes how people think about metabolism, aging, or recovery is probably already out there. It might be sitting in a trial somewhere, or sitting in this catalog right now scoring in the thirties because the human data hasn't caught up to the interest yet. Finding it early, and reading it honestly before the marketing arrives to tell you what to think, is the whole point of what we're doing here. I'd rather discover it alongside you than sell it to you.

Let's get into it.

Every so often I look at what's actually bringing people to the site, and one compound has been quietly climbing the list: Gonadorelin. Almost every search attached to it is some version of the same question, and that question is about fertility. That tracks, because fertility is the most legitimate thing Gonadorelin does. It's also where the story gets more complicated than most of the content around it lets on.

What it is. Gonadorelin is a synthetic copy of gonadotropin-releasing hormone, or GnRH, the signal your own hypothalamus sends to your pituitary to run the entire reproductive axis. It's a short chain of ten amino acids, identical to the natural hormone. When it reaches the pituitary in the right rhythm, it triggers the release of luteinizing hormone and follicle-stimulating hormone, and those two downstream signals are what actually drive the testes and ovaries: testosterone and sperm production in men, the follicular cycle and ovulation in women. So Gonadorelin doesn't replace any of those hormones. It sits one level up the chain and tells the body to make its own.

The detail that matters most, and that most content skips. The effect depends entirely on rhythm. Delivered in natural pulses, GnRH switches the reproductive axis on. Delivered continuously, at a flat and steady level, it does the opposite: the pituitary receptors downregulate and the whole axis shuts down. This is not a footnote. It's the reason the exact same molecule is used both to support fertility and, in a different delivery pattern, to suppress the reproductive axis on purpose in conditions like endometriosis and prostate cancer. A compound whose effect can reverse depending on how it's timed is not one to approach casually, and it is the single most important thing to understand before the word "fertility" gets attached to it.

The regulatory history is real. This is one of the few compounds in the catalog with a genuine FDA approval history. Gonadorelin was approved decades ago, in one form as a diagnostic tool for evaluating pituitary function, and in another as a pulsatile therapy delivered by pump to induce ovulation in women whose cycles had stopped because of a hypothalamic signaling problem. The branded products have largely left the US market since then, for commercial rather than safety reasons, but the clinical evidence base underneath GnRH as a fertility tool is decades deep and academically serious. That history is a big part of why it scores where it does.

Where the popular use and the studied use diverge. Here's the honest tension. Most of the current interest in Gonadorelin is not coming from the fertility clinic. It's coming from the testosterone optimization world, where it's used off-label to keep the natural axis running while someone is on exogenous testosterone, or to restart it afterward, largely as a substitute for hCG. There's real physiological logic to that, and it isn't fringe biology. But it's a genuinely different use than the one the approval history and the strongest trials were built on, and the direct, high quality human evidence for that specific application is much thinner than the confident content around it suggests. The reputation of the well studied use is quietly doing a lot of work for the less studied one. That gap is exactly the kind of thing the RQS exists to make visible.

The score. Gonadorelin sits at 77, in the Moderate band, one of the higher scores in the catalog. That reflects a real clinical evidence base, genuine trial history, and prior regulatory review, tempered by the fact that much of that evidence lives in specific studied indications rather than the general purpose axis support use driving most of the current search interest. As always, Moderate does not mean proven for everything, and it does not mean safe. It means the human research behind this compound carries real methodological weight, more than most things people get excited about, in the uses that were actually studied. The RQS measures research quality and nothing else.

One thing I won't do, and it matters more here than almost anywhere. I'm not going to give you a protocol, a dose, or a stack. Not out of caution for its own sake, but because for the axis-support use most people are asking about, the formal protocols largely don't exist, and they don't exist because the trials that would have established them were never run. Anyone handing you a precise Gonadorelin protocol for fertility preservation is filling that gap with confidence, not data. This is a compound that acts directly on the reproductive axis, where the timing of a dose can flip the effect from stimulation to suppression. That is a conversation for a physician who can actually monitor what your hormones are doing, not for a newsletter and not for a forum thread.

RQS: 77/100 - Moderate Evidence

Read the full Gonadorelin profile

The claim: A red light panel or LED mask is close to a universal upgrade. Depending on which video you land on, it melts fat, smooths wrinkles, regrows hair, raises testosterone, speeds muscle recovery, improves sleep, and lifts your mood, all from sitting in front of a glowing panel for ten minutes a day. It's one of the fastest-growing categories in the wellness-device market, and the pitch is almost always the same shape: one device, one mechanism, a very long list of benefits.

The reality: This is a more interesting case than the usual debunk, because the underlying mechanism is real and specific, and some of the claims genuinely hold up. That's precisely what makes the overreach effective.

Start with the mechanism, because it's legitimate. Red and near-infrared light in roughly the 600 to 1000 nanometer range penetrates tissue and gets absorbed by an enzyme in your mitochondria called cytochrome c oxidase. That absorption nudges cellular energy production, nitric oxide release, and reactive oxygen signaling. The process has a name, photobiomodulation, and it's real cell biology with decades of study behind it. This is not homeopathy. Something measurable happens when red light hits tissue.

Now the part the marketing collapses. A real mechanism does not mean every claimed outcome is real, and the evidence is wildly uneven across that long list.

Where it holds up: skin. This is the strongest evidence in the whole category. Multiple controlled trials, including a well-known 2014 study of more than a hundred participants, show measurable reductions in wrinkle depth and increases in collagen density confirmed by ultrasound, over eight to twelve weeks of consistent use. The effects are real, they're gradual, and they fade within about a month if you stop. There's also reasonable support for red light in androgenetic hair loss, where several devices actually hold FDA clearance, and for acne when it's combined with blue light. For skin and hair, matched to realistic expectations, the human evidence is genuinely there.

Where it does not hold up nearly as well: fat loss. This is the claim doing the most commercial work while resting on the weakest foundation. The FDA clearances that get cited are for temporary reductions in circumference, inches off a waist measurement, not fat loss and not weight loss, and the effect is local, modest, and short-lived. More to the point, a large share of the positive body contouring studies were funded directly by the companies selling the devices. No peer reviewed randomized trial has shown meaningful fat loss from the at home LED panels most people are actually buying. And the systemic claims at the far end, the testosterone boosts and metabolic transformations, are the thinnest of all, extrapolated from mechanism or from tiny uncontrolled studies rather than actually demonstrated.

You'll notice a familiar theme. When the company selling the device also funds the study proving it works, that doesn't automatically make the result wrong, but it tells you how much weight to put on it. That's the exact instinct behind the Funding Independence dimension in the RQS, and it applies to a hardware trial the same way it applies to a peptide paper.

The honest version of the claim: The mechanism is real, and for skin, and to a lesser degree hair, the human evidence holds up well enough to justify the purchase if your expectations are calibrated. But the device is being sold as a whole-body upgrade on the strength of evidence that only exists for a narrow slice of what's promised, and the single most-marketed benefit, fat loss, rests largely on manufacturer-funded studies of a temporary, local effect. Buy it for your skin and it may well deliver. Buy it to melt fat or raise your testosterone and you're paying for a mechanism, not a result.

The vendor log quietly passed a milestone worth explaining. As of this batch, the Vendor Transparency Score log now covers more vendors than the site most AI assistants reach for when someone asks about peptide vendor transparency. That sounds like a bragging point and I don't want to frame it as one, because the interesting part isn't the count. It's the gap it exposes. When you ask an AI which vendors are transparent, it tends to point you at whatever source it was trained to recognize, and that source is not necessarily the most comprehensive one, or the most independent one, or the one without affiliate relationships attached. The most-cited reference and the most-complete reference have quietly stopped being the same thing. I'd rather the log earn its place by being larger, more current, and genuinely conflict-free than by being the name a model happens to know. Every vendor added is one fewer blind spot for anyone trying to make a real sourcing decision. The full log, with every dimension broken out and every source linked, is on the methodology page.

The GLP-1 fertility story is worth watching, and it connects to today's lead. There's a growing pattern that's been nicknamed "Ozempic babies": women reporting unexpected pregnancies while on GLP-1 drugs. Two separate things appear to be driving it, and neither is the drug acting as a fertility treatment. The first is straightforward. Meaningful weight loss and metabolic improvement can restore ovulation in people who weren't ovulating regularly, which is especially relevant in PCOS. The second is more of a warning: at least one study found that tirzepatide delayed absorption of the combined oral contraceptive pill and lowered blood levels of one of its active ingredients, which is why the manufacturer recommends backup non-oral contraception for a stretch after starting or increasing the dose. I flag it because it sits right at the intersection of the two themes in this issue, the mainstreaming of GLP-1s and the fertility questions people are quietly searching, and because it's a clean example of a real, physiological effect that most of the marketing around these drugs never mentions.

The FDA rule-making clock is still the number to watch. Nothing has legally changed since July's advisory vote on the six recommended compounds. The next real signal is whether the agency indicates it intends to open formal rule making at all, and historically that first step alone has taken well over a year. In the meantime, expect "FDA approved," "FDA cleared," and "now legal" to keep appearing on product pages for those compounds. All of it remains false today, and a vendor making that leap is telling you something useful about how it handles claims in general.

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.